Document is current
Any future updates will be listed below
-
Authors
Spichiger, Frank
Meichtry, André
Larkin, Philip
Koppitz, Andrea
-
Funding
Funding for this research was provided by:
HES-SO University of Applied Science and Arts Western Switzerland Bureau d’appui et de coordination de la formation doctorale (R_2023-08-25)
Schweizerische Akademie der Medizinischen Wissenschaften,Switzerland (PC 20/17)
Gottfried und Julia Bangerter-Rhyner-Stiftung,Switzerland (PC 20/17)
Swiss Academy for Socratic Care
- License Information
-
More Information
Article History
Received: 12 October 2023
Accepted: 13 February 2025
First Online: 22 February 2025
Declarations
:
: All participants were required to provide informed consent and sign a consent form before data collection. The consent form and study materials were approved by the relevant Ethics Committee of the Canton of Zürich. The trial was approved by the Swiss Regional Ethics Committee of the Canton of Zürich on 12 November 2019, serving as the leading ethics committee for the involved regions, with clearance certification number BASEC2019-01847. The main study and secondary analysis were registered with the German Clinical Trials Register (DRKS00022339). Full registration details can be accessed online at . The trial was planned and conducted in accordance with the European Medicines Agency Good Clinical Practice Guidelines [], which are based on the Declaration of Helsinki [].
: All participants provided informed consent for publication via an informed consent form before data collection.
: AK and FS are the translators/developers of the Swiss easy-read IPOS-Dem. The Swiss easy-read IPOS-Dem is a secondary outcome measure in a trial, where AK is the principal investigator. AM and PL have no conflicts of interest to disclose.
